49 81

Cited 3 times in

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Authors
 Sun Min Lim  ;  Solange Peters  ;  Ana Laura Ortega Granados  ;  Gustavo Dix Junqueira Pinto  ;  Christian Sebastián Fuentes  ;  Giuseppe Lo Russo  ;  Michael Schenker  ;  Jin Seok Ahn  ;  Martin Reck  ;  Zsolt Szijgyarto  ;  Neda Huseinovic  ;  Eleftherios Zografos  ;  Elena Buss  ;  Neda Stjepanovic  ;  Sean O'Donnell  ;  Filippo de Marinis 
Citation
 NATURE COMMUNICATIONS, Vol.14(1) : 7301, 2023-11 
Journal Title
NATURE COMMUNICATIONS
Issue Date
2023-11
MeSH
Antineoplastic Combined Chemotherapy Protocols / adverse effects ; B7-H1 Antigen ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Humans ; Lung Neoplasms* / pathology
Abstract
PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations. Patients stratified by PD-L1 tumor proportion score and smoking status were randomized 1:1, receiving ≤35 cycles 500 mg dostarlimab or 200 mg pembrolizumab, ≤35 cycles 500 mg/m2 pemetrexed and ≤4 cycles cisplatin (75 mg/m2) or carboplatin (AUC 5 mg/ml/min) Q3W. Primary endpoint was overall response rate (ORR) (blinded independent central review). Secondary endpoints include progression-free survival (PFS) based on investigator assessment, overall survival (OS) and safety. Exploratory endpoints include ORR by PD-L1 subgroup and duration of response. PERLA met its pre-specified endpoint. ORR (n/N; 95% CI) is 45% (55/121; 36.4–54.8) for DCT and 39% (48/122; 30.6–48.6) for PCT (data cut-off: 07 July 23), numerically favoring dostarlimab in PD-L1-positive subgroups. Median PFS (months [95% CI]) is 8.8 (6.7–10.4) for DCT and 6.7 (4.9–7.1) for PCT (HR 0.70 [95% CI: 0.50–0.98]; data cut-off: 04 August 22). Median OS (months [95% CI]) is 19.4 (14.5–NR) for DCT and 15.9 (11.6–19.3) for PCT (HR 0.75 [95% CI: 0.53–1.05]) (data cut-off: 07 July 23). Safety profiles are similar between groups. In this study, DCT shows similar efficacy to PCT and demonstrates clinical efficacy as first-line treatment for patients with metastatic non-squamous NSCLC. © 2023, The Author(s).
Files in This Item:
T202400787.pdf Download
DOI
10.1038/s41467-023-42900-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lim, Sun Min(임선민)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/198024
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links